Transcenta Receives First Payment for CDMO Asset Sale

MT Newswires Live10-20

Transcenta (HKG:6628) has received the first payment of 95 million yuan, net of tax, for the sale of its contract development and manufacturing organization (CDMO) assets to a subsidiary of WuXi Biologics (HKG:2269), according to a Tuesday Hong Kong bourse filing.

The asset sale carries a total consideration of 190 million yuan, subject to adjustments.

Transcenta said it expects to receive additional proceeds before the end of 2026, subject to the terms of the agreement.

The company said the disposal is expected to reduce staff costs and operating expenses in 2027 compared with 2026.

The proceeds will support general working capital and pipeline development.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment